Stimulants (also known as central nervous system stimulants, or psychostimulants, or colloquially as uppers) are a class of psychoactive drugs that increase alertness. They are used for various purposes, such as enhancing attention, motivation, cognition, mood, and physical performance. Some stimulants occur naturally, while others are exclusively synthetic. Common stimulants include caffeine, nicotine, cocaine (including crack cocaine), amphetamine/methamphetamine, methylphenidate, and modafinil. Stimulants may be subject to varying forms of regulation, or outright prohibition, depending on jurisdiction. Most stimulants are highly addictive and damage health when addicted.
Stimulants increase activity in the sympathetic nervous system, either directly or indirectly. Prototypical stimulants increase synaptic concentrations of excitatory neurotransmitters, particularly norepinephrine and dopamine (e.g., methylphenidate). Other stimulants work by binding to the receptors of excitatory neurotransmitters (e.g., nicotine) or by blocking the activity of endogenous agents that promote sleep (e.g., caffeine). Stimulants can affect various functions, including arousal, attention, the reward system, learning, memory, and emotion. Effects range from mild stimulation to euphoria, depending on the specific drug, dose, route of administration, and inter-individual characteristics.
Stimulants have a long history of use, both for medical and non-medical purposes. Archeological evidence from Peru shows that cocaine use dates back as far as 8000 B.C.E.[1] Stimulants have been used to treat various conditions, such as narcolepsy, attention deficit hyperactivity disorder (ADHD), obesity, depression, and fatigue. They have also been used as recreational drugs, performance-enhancing substances, and cognitive enhancers, by various groups of people, such as students, athletes, artists, and workers. They have also been used to promote aggression of combatants in wartime, both historically and in the present day.[2][3][4]
Stimulants have potential risks and side effects, such as addiction, tolerance, withdrawal, psychosis, anxiety, insomnia, cardiovascular problems, and neurotoxicity. The misuse and abuse of stimulants can lead to serious health and social consequences, such as overdose, dependence, crime, and violence. Therefore, the use of stimulants is regulated by laws and policies in most countries, and requires medical supervision and prescription in some cases.
Stimulant is an overarching term that covers many drugs including those that increase the activity of the central nervous system and the body,[5] drugs that are pleasurable and invigorating, or drugs that have sympathomimetic effects.[6] Sympathomimetic effects are those effects that mimic or copy the actions of the sympathetic nervous system. The sympathetic nervous system is a part of the nervous system that prepares the body for action, such as increasing the heart rate, blood pressure, and breathing rate. Stimulants can activate the same receptors as the natural chemicals released by the sympathetic nervous system (namely epinephrine and norepinephrine) and cause similar effects.[7]
Psychostimulant refers to a subset of substances within the stimulant drug class that act at the dopamine transporter (DAT), a protein that normally clears dopamine from the synaptic cleft.[8][9] Amphetamine, methylphenidate, cocaine, and modafinil are examples of psychostimulants that promote arousal and affect task performance in a dose-dependent manner.[8][10] Psychostimulants act at DAT by inhibiting dopamine reuptake or by initiating transporter-mediated dopamine efflux (i.e., reverse transport), thereby producing indirect dopamine agonist effects in the central nervous system.[8][9] The DAT-mediated actions of psychostimulants contrast with other central nervous system stimulants that can overlap in behavioural effects, such as caffeine, a drug that promotes wakefulness primarily through antagonism of adenosine receptors.[10]
Effects
Acute
Stimulants in low doses, such as those prescribed to treat attention deficit hyperactivity disorder (ADHD), increase ability to focus, vigor, sociability, wakefulness, libido and may elevate mood or cause euphoria. However, in higher doses, stimulants may actually decrease the ability to focus, a principle of the Yerkes-Dodson law.[11]
Many, but not all, stimulants have ergogenic effects; that is, they enhance physical performance. Drugs such as ephedrine, pseudoephedrine, amphetamine and methylphenidate have well documented ergogenic effects, while cocaine has the opposite effect.[12]
Neurocognitive enhancing effects of stimulants, specifically modafinil, amphetamine and methylphenidate have been reported in healthy adolescents by some studies,[13] and is a commonly cited reason among illicit drug users for use, particularly among college students in the context of studying.[13] Still, results of these studies is inconclusive: assessing the potential overall neurocognitive benefits of stimulants among healthy youth is challenging due to the diversity within the population, the variability in cognitive task characteristics, and the absence of replication of studies.[13] Research on the cognitive enhancement effects of modafinil in healthy non-sleep-deprived individuals has yielded mixed results, with some studies suggesting modest improvements in attention and executive functions while others show no significant benefits or even a decline in cognitive functions.[14][15][16]
In some cases, psychiatric phenomena may emerge such as stimulant psychosis, paranoia, and suicidal ideation. Acute toxicity has been reportedly associated with hyperhydrosis, panic attacks, severe anxiety, mydriasis, paranoia, aggressive behavior, excessive motor activity, psychosis, rhabdomyolysis, and punding. The violent and aggressive behavior associated with acute stimulant toxicity may partially be driven by paranoia.[17] Most drugs classified as stimulants are sympathomimetic, meaning that they stimulate the sympathetic branch of the autonomic nervous system. This leads to effects such as mydriasis (dilation of the pupils), increased heart rate, blood pressure, respiratory rate and body temperature.[6] When these changes become pathological, they are called arrhythmia, hypertension, and hyperthermia, and may lead to rhabdomyolysis, stroke, cardiac arrest, or seizures. However, given the complexity of the mechanisms that underlie these potentially fatal outcomes of acute stimulant toxicity, it is impossible to determine what dose may be lethal.[18]
Chronic
Assessment of the effects of stimulants is relevant given the large population currently taking stimulants. A 2022 meta-analysis with a sample size of just under four million people found no association between the use of prescription psychostimulants and the development of cardiovascular disease in any age group.[19] A review of a year long period of prescription stimulant use in those with ADHD found that cardiovascular side effects were limited to transient increases in blood pressure only.[20] However, a 2024 systematic review of the evidence found that stimulants overall improve ADHD symptoms and broadband behavioral measures in children and adolescents, though they carry risks of side effects like appetite suppression and other adverse events.[21] Initiation of stimulant treatment in those with ADHD in early childhood appears to carry benefits into adulthood with regard to social and cognitive functioning, and appears to be relatively safe.[22]
Abuse of prescription stimulants (not following physician instruction) or of illicit stimulants carries many negative health risks. Abuse of cocaine, depending upon route of administration, increases risk of cardiorespiratory disease, stroke, and sepsis.[23] Some effects are dependent upon the route of administration, with intravenous use associated with the transmission of many disease such as Hepatitis C, HIV/AIDS and potential medical emergencies such as infection, thrombosis or pseudoaneurysm,[24] while inhalation may be associated with increased lower respiratory tract infection, lung cancer, and pathological restricting of lung tissue.[25] Cocaine may also increase risk for autoimmune disease[26][27][28] and damage nasal cartilage. Abuse of methamphetamine produces similar effects as well as marked degeneration of dopaminergic neurons, resulting in an increased risk for Parkinson's disease.[29][30][31][32]
Medical uses
Stimulants are widely used throughout the world as prescription medicines as well as without a prescription (either legally or illicitly) as performance-enhancing or recreational drugs. Among narcotics, stimulants produce a noticeable crash or comedown at the end of their effects. In the US, the most frequently prescribed stimulants as of 2013 were lisdexamfetamine (Vyvanse), methylphenidate (Ritalin), and amphetamine (Adderall).[33] It was estimated in 2015 that the percentage of the world population that had used cocaine during a year was 0.4%. For the category "amphetamines and prescription stimulants" (with "amphetamines" including amphetamine and methamphetamine) the value was 0.7%, and for MDMA 0.4%.[34]
Stimulants have been used in medicine for many conditions including obesity, sleep disorders, mood disorders, impulse control disorders, asthma, nasal congestion and, in case of cocaine, as local anesthetics.[35] Drugs used to treat obesity are called anorectics and generally include drugs that follow the general definition of a stimulant, but other drugs such as cannabinoid receptor antagonists also belong to this group.[36][37]Eugeroics are used in management of sleep disorders characterized by excessive daytime sleepiness, such as narcolepsy, and include stimulants such as modafinil and pitolisant.[38][39] Stimulants are used in impulse control disorders such as ADHD[40] and off-label in mood disorders such as major depressive disorder to increase energy, focus and elevate mood.[41] Stimulants such as epinephrine,[42]theophylline and salbutamol[43] orally have been used to treat asthma, but inhaled adrenergic drugs are now preferred due to less systemic side effects. Pseudoephedrine is used to relieve nasal or sinus congestion caused by the common cold, sinusitis, hay fever and other respiratory allergies; it is also used to relieve ear congestion caused by ear inflammation or infection.[44][45]
Depression
Stimulants were one of the first classes of drugs to be used in the treatment of depression, beginning after the introduction of the amphetamines in the 1930s.[46][47][48] However, they were largely abandoned for treatment of depression following the introduction of conventional antidepressants in the 1950s.[46][47] Subsequent to this, there has been a resurgence in interest in stimulants for depression in recent years.[49][50]
Stimulants produce a fast-acting and pronounced but transient and short-lived mood lift.[51][52][49][47] In relation to this, they are minimally effective in the treatment of depression when administered continuously.[51][52] In addition, tolerance to the mood-lifting effects of amphetamine has led to dose escalation and dependence.[50] Although the efficacy for depression with continuous administration is modest, it may still reach statistical significance over placebo and provide benefits similar in magnitude to those of conventional antidepressants.[53][54][55][56] The reasons for the short-term mood-improving effects of stimulants are unclear, but may relate to rapid tolerance.[51][52][47][57] Tolerance to the effects of stimulants has been studied and characterized both in animals[57][58][59][60] and humans.[61][62][63][64] Stimulant withdrawal is remarkably similar in its symptoms to those of major depressive disorder.[65][57][66][67]
Amphetamine-type stimulants are often used for their therapeutic effects. Physicians sometimes prescribe amphetamine to treat major depressive disorder, where subjects do not respond well to traditional selective serotonin reuptake inhibitor (SSRI) medications, but evidence supporting this use is mixed.[50] Two large phase III studies of lisdexamfetamine (a prodrug to amphetamine) as an adjunct to an SSRI or serotonin–norepinephrine reuptake inhibitor (SNRI) in the treatment of major depressive disorder showed no further benefit relative to placebo in effectiveness.[75] Numerous studies have demonstrated the effectiveness of drugs like Adderall (a mixture of salts of amphetamine and dextroamphetamine) in controlling symptoms associated with ADHD. Non-stimulants such as atomoxetine have also found to be effective.[76] Due to their availability and fast-acting effects, substituted amphetamines are prime candidates for abuse.[77]
Cocaine analogs
Hundreds of cocaine analogs have been created, all of them usually maintaining a benzyloxy connected to the 3 carbon of a tropane. Various modifications include substitutions on the benzene ring, as well as additions or substitutions in place of the normal carboxylate on the tropane 2 carbon. Various compound with similar structure activity relationships to cocaine that aren't technically analogs have been developed as well.
Mechanisms of action
Most stimulants exert their activating effects by enhancing catecholamine neurotransmission. Catecholamine neurotransmitters are employed in regulatory pathways implicated in attention, arousal, motivation, task salience and reward anticipation. Classical stimulants either block the reuptake or stimulate the efflux of these catecholamines, resulting in increased activity of their circuits. Some stimulants, specifically those with entactogenic and hallucinogenic effects, also affect serotonergic transmission. Some stimulants, such as some amphetamine derivatives[which?] and, notably, yohimbine, can decrease negative feedback by antagonizing regulatory autoreceptors.[78] Adrenergic agonists, such as, in part, ephedrine, act by directly binding to and activating adrenergic receptors, producing sympathomimetic effects.
The precise mechanism of action of some stimulants, such as modafinil, for treating symptoms of narcolepsy and other sleep disorders, remains unknown.[80][81][82][83][84]
Amphetamine is a potent psychostimulant of the phenethylamine class that is approved for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy.[85] Amphetamine is also used off-label as a performance and cognitive enhancer, and recreationally as an aphrodisiac and euphoriant.[86][87][88][89] Although it is a prescription medication in many countries, unauthorized possession and distribution of amphetamine is often tightly controlled due to the significant health risks associated with uncontrolled or heavy use.[90][91] As a consequence, amphetamine is illegally manufactured in clandestine labs to be trafficked and sold to users.[92] Based upon drug and drug precursor seizures worldwide, illicit amphetamine production and trafficking is much less prevalent than that of methamphetamine.[92]
The first pharmaceutical amphetamine was Benzedrine, a brand of inhalers used to treat a variety of conditions.[93][94] Because the dextrorotary isomer has greater stimulant properties, Benzedrine was gradually discontinued in favor of formulations containing all or mostly dextroamphetamine. Presently, it is typically prescribed as mixed amphetamine salts, dextroamphetamine, and lisdexamfetamine.[93][95]
Amphetamine is a norepinephrine-dopamine releasing agent (NDRA). It enters neurons through dopamine and norepinephrine transporters and facilitates neurotransmitter efflux by activating TAAR1 and inhibiting VMAT2.[73] At therapeutic doses, this causes emotional and cognitive effects such as euphoria, change in libido, increased arousal, and improved cognitive control.[87][88][96] Likewise, it induces physical effects such as decreased reaction time, fatigue resistance, and increased muscle strength.[86] In contrast, supratherapeutic doses of amphetamine are likely to impair cognitive function and induce rapid muscle breakdown.[85][87][97] Very high doses can result in psychosis (e.g., delusions and paranoia), which very rarely occurs at therapeutic doses even during long-term use.[98][99] As recreational doses are generally much larger than prescribed therapeutic doses, recreational use carries a far greater risk of serious side effects, such as dependence, which only rarely arises with therapeutic amphetamine use.[85][97][98]
Roasted coffee beans, a common source of caffeine.
Caffeine is a stimulant compound belonging to the xanthine class of chemicals naturally found in coffee, tea, and (to a lesser degree) cocoa or chocolate. It is included in many soft drinks, as well as a larger amount in energy drinks. Caffeine is the world's most widely used psychoactive drug and by far the most common stimulant. In North America, 90% of adults consume caffeine daily.[100]
A few jurisdictions restrict the sale and use of caffeine. In the United States, the FDA has banned the sale of pure and highly concentrated caffeine products for personal consumption, due to the risk of overdose and death.[101] The Australian Government has announced a ban on the sale of pure and highly concentrated caffeine food products for personal consumption, following the death of a young man from acute caffeine toxicity.[102][103] In Canada, Health Canada has proposed to limit the amount of caffeine in energy drinks to 180 mg per serving, and to require warning labels and other safety measures on these products.[102]
Caffeine is also included in some medications, usually for the purpose of enhancing the effect of the primary ingredient,[104] or reducing one of its side-effects (especially drowsiness).[105] Tablets containing standardized doses of caffeine are also widely available.[106]
Caffeine's mechanism of action differs from many stimulants, as it produces stimulant effects by inhibiting adenosine receptors.[107] Adenosine receptors are thought to be a large driver of drowsiness and sleep, and their action increases with extended wakefulness.[108] Caffeine has been found to increase striatal dopamine in animal models,[109] as well as inhibit the inhibitory effect of adenosine receptors on dopamine receptors,[110] however the implications for humans are unknown. Unlike most stimulants, caffeine has no addictive potential. Caffeine does not appear to be a reinforcing stimulus, and some degree of aversion may actually occur, per a study on drug abuse liability published in an NIDA research monograph that described a group preferring placebo over caffeine.[111] In large telephone surveys only 11% reported dependence symptoms. However, when people were tested in labs, only half of those who claim dependence actually experienced it, casting doubt on caffeine's ability to produce dependence and putting societal pressures in the spotlight.[112]
Coffee consumption is associated with a lower overall risk of cancer.[113] This is primarily due to a decrease in the risks of hepatocellular and endometrial cancer, but it may also have a modest effect on colorectal cancer.[114] There does not appear to be a significant protective effect against other types of cancers, and heavy coffee consumption may increase the risk of bladder cancer.[114] A protective effect of caffeine against Alzheimer's disease is possible, but the evidence is inconclusive.[115][116][117] Moderate coffee consumption may decrease the risk of cardiovascular disease,[118] and it may somewhat reduce the risk of type 2 diabetes.[119] Drinking 1–3 cups of coffee per day does not affect the risk of hypertension compared to drinking little or no coffee. However those who drink 2–4 cups per day may be at a slightly increased risk.[120] Caffeine increases intraocular pressure in those with glaucoma but does not appear to affect normal individuals.[121] It may protect people from liver cirrhosis.[122] There is no evidence that coffee stunts a child's growth.[123] Caffeine may increase the effectiveness of some medications including ones used to treat headaches.[124] Caffeine may lessen the severity of acute mountain sickness if taken a few hours prior to attaining a high altitude.[125]
In chemical terms, it is an alkaloid with a phenethylamine skeleton found in various plants in the genus Ephedra (family Ephedraceae). It works mainly by increasing the activity of norepinephrine (noradrenaline) on adrenergic receptors.[126] It is most usually marketed as the hydrochloride or sulfate salt.
The herb má huáng (Ephedra sinica), used in traditional Chinese medicine (TCM), contains ephedrine and pseudoephedrine as its principal active constituents. The same may be true of other herbal products containing extracts from other Ephedra species.
3,4-Methylenedioxymethamphetamine (MDMA, ecstasy, or molly) is an entactogen, euphoriant, and psychostimulant of the amphetamine class.[9][127] Briefly used by some psychotherapists as an adjunct to therapy, the drug became popular recreationally and the DEA listed MDMA as a Schedule I controlled substance, prohibiting most medical studies and applications. MDMA is known for its entactogenic properties. The stimulant effects of MDMA include hypertension, anorexia (appetite loss), euphoria, social disinhibition, insomnia (enhanced wakefulness/inability to sleep), improved energy, increased arousal, and increased perspiration, among others. Relative to catecholaminergic transmission, MDMA enhances serotonergic transmission significantly more, when compared to similar psychostimulants like amphetamine.[9]
Due to the relative safety of MDMA, some researchers such as David Nutt have criticized the scheduling level, writing a satirical article finding MDMA to be 28 times less dangerous than horseriding, a condition he termed "equasy" or "Equine Addiction Syndrome".[128]
Methylenedioxypyrovalerone (MDPV) is a psychoactive drug with stimulant properties that acts as a norepinephrine-dopamine reuptake inhibitor (NDRI).[129] It was first developed in the 1960s by a team at Boehringer Ingelheim.[130] MDPV remained an obscure stimulant until around 2004, when it was reported to be sold as a designer drug. Products labeled as bath salts containing MDPV were previously sold as recreational drugs in gas stations and convenience stores in the United States, similar to the marketing for Spice and K2 as incense.[131][132]
Incidents of psychological and physical harm have been attributed to MDPV use.[133][134]
Mephedrone is a synthetic stimulant drug of the amphetamine and cathinone classes. Slang names include drone[135] and MCAT.[136] It is reported to be manufactured in China and is chemically similar to the cathinone compounds found in the khat plant of eastern Africa. It comes in the form of tablets or a powder, which users can swallow, snort, or inject, producing similar effects to MDMA, amphetamines, and cocaine.
Mephedrone was first synthesized in 1929, but did not become widely known until it was rediscovered in 2003. By 2007, mephedrone was reported to be available for sale on the Internet; by 2008 law enforcement agencies had become aware of the compound; and, by 2010, it had been reported in most of Europe, becoming particularly prevalent in the United Kingdom. Mephedrone was first made illegal in Israel in 2008, followed by Sweden later that year. In 2010, it was made illegal in many European countries, and, in December 2010, the EU ruled it illegal. In Australia, New Zealand, and the US, it is considered an analog of other illegal drugs and can be controlled by laws similar to the Federal Analog Act. In September 2011, the USA temporarily classified mephedrone as illegal, in effect from October 2011.
Mephedrone is neurotoxic and has abuse potential, predominantly exerted on 5-hydroxytryptamine (5-HT) terminals, mimicking that of MDMA with which it shares the same subjective sensations on abusers.[137][138][139]
Methamphetamine (contracted from N-methyl-alpha-methylphenethylamine) is a potent psychostimulant of the phenethylamine and amphetamineclasses that is used to treat attention deficit hyperactivity disorder (ADHD) and obesity.[140][141][142] Methamphetamine exists as two enantiomers, dextrorotary and levorotary.[143][144] Dextromethamphetamine is a stronger CNS stimulant than levomethamphetamine;[97][143][144] however, both are addictive and produce the same toxicity symptoms at high doses.[144] Although rarely prescribed due to the potential risks, methamphetamine hydrochloride is approved by the United States Food and Drug Administration (USFDA) under the trade name Desoxyn.[141] Recreationally, methamphetamine is used to increase sexual desire, lift the mood, and increase energy, allowing some users to engage in sexual activity continuously for several days straight.[141][145]
Methamphetamine may be sold illicitly, either as pure dextromethamphetamine or in an equal parts mixture of the right- and left-handed molecules (i.e., 50% levomethamphetamine and 50% dextromethamphetamine).[145] Both dextromethamphetamine and racemic methamphetamine are schedule II controlled substances in the United States.[141] Also, the production, distribution, sale, and possession of methamphetamine is restricted or illegal in many other countries due to its placement in schedule II of the United Nations Convention on Psychotropic Substances treaty.[146][147] In contrast, levomethamphetamine is an over-the-counter drug in the United States.[note 1]
In low doses, methamphetamine can cause an elevated mood and increase alertness, concentration, and energy in fatigued individuals.[97][141] At higher doses, it can induce psychosis, rhabdomyolysis, and cerebral hemorrhage.[97][141] Methamphetamine is known to have a high potential for abuse and addiction.[97][141] Recreational use of methamphetamine may result in psychosis or lead to post-withdrawal syndrome, a withdrawal syndrome that can persist for months beyond the typical withdrawal period.[150] Unlike amphetamine and cocaine, methamphetamine is neurotoxic to humans, damaging both dopamine and serotonin neurons in the central nervous system (CNS).[140][142] Unlike the long-term use of amphetamine in prescription doses, which may improve certain brain regions in individuals with ADHD, there is evidence that methamphetamine causes brain damage from long-term use in humans;[140][142] this damage includes adverse changes in brain structure and function, such as reductions in gray matter volume in several brain regions and adverse changes in markers of metabolic integrity.[151][152][142]
Methylphenidate is a psychostimulant drug that is often used in the treatment of ADHD and narcolepsy and occasionally to treat obesity in combination with diet restraints and exercise. Its effects at therapeutic doses include increased focus, increased alertness, decreased appetite, decreased need for sleep and decreased impulsivity. Methylphenidate is not usually used recreationally, but when it is used, its effects are very similar to those of amphetamines.[9]
Methylphenidate acts as a norepinephrine-dopamine reuptake inhibitor (NDRI), by blocking the norepinephrine transporter (NET) and the dopamine transporter (DAT). Methylphenidate has a higher affinity for the dopamine transporter than for the norepinephrine transporter, and so its effects are mainly due to elevated dopamine levels caused by the inhibited reuptake of dopamine, however increased norepinephrine levels also contribute to various of the effects caused by the drug.
Methylphenidate is sold under a number of brand names including Ritalin. Other versions include the long lasting tablet Concerta and the long lasting transdermal patch Daytrana.
Cocaine is an SNDRI. Cocaine is made from the leaves of the coca shrub, which grows in the mountain regions of South American countries such as Bolivia, Colombia, and Peru, regions in which it was cultivated and used for centuries mainly by the Aymara people. In Europe, North America, and some parts of Asia, the most common form of cocaine is a white crystalline powder. Cocaine is a psychostimulant but is not normally prescribed therapeutically for its stimulant properties, although it sees clinical use as a local anesthetic, in particular in ophthalmology.[8][153] Most cocaine use is recreational and its abuse potential is high (higher than amphetamine), and so its sale and possession are strictly controlled in most jurisdictions. Other tropane derivative drugs related to cocaine are also known such as troparil and lometopane but have not been widely sold or used recreationally.[154]
Nicotine is the active chemical constituent in tobacco, which is available in many forms, including cigarettes, cigars, chewing tobacco, and smoking cessation aids such as nicotine patches, nicotine gum, and electronic cigarettes. Nicotine is used widely throughout the world for its stimulating and relaxing effects. Nicotine exerts its effects through the agonism of nicotinic acetylcholine receptors, resulting in multiple downstream effects such as increase in activity of dopaminergic neurons in the midbrain reward system, and acetaldehyde one of the tobacco constituent decreased the expression of monoamine oxidase in the brain.[155] Nicotine is addictive and dependence forming. Tobacco, the most common source of nicotine, has an overall harm to user and self score 3 percent below cocaine, and 13 percent above amphetamines, ranking 6th most harmful of the 20 drugs assessed, as determined by a multi-criteria decision analysis.[156]
In the United States, PPA is no longer sold without a prescription due to a possible increased risk of stroke in younger women. In a few countries in Europe, however, it is still available either by prescription or sometimes over-the-counter. In Canada, it was withdrawn from the market on 31 May 2001.[158] In India, human use of PPA and its formulations were banned on 10 February 2011.[159]
Lisdexamfetamine (Vyvanse, etc.) is an amphetamine-type medication, sold for use in treating ADHD.[160] Its effects typically last around 14 hours.[161] Lisdexamfetamine is inactive on its own and is metabolized into dextroamphetamine in the body.[62] Consequently, it has a lower abuse potential (i.e., reduced effects from parenteral administration).[62]
Khat contains a monoamine alkaloid called cathinone, a "keto-amphetamine". This alkaloid causes excitement, loss of appetite, and euphoria. In 1980, the World Health Organization (WHO) classified it as a drug of abuse that can produce mild to moderate psychological dependence (less than tobacco or alcohol),[166] although the WHO does not consider khat to be seriously addictive.[165] It is banned in some countries, such as the United States, Canada, and Germany, while its production, sale, and consumption are legal in other countries, including Djibouti, Ethiopia, Somalia, Kenya and Yemen.[167]
Modafinil is an eugeroic medication, which means that it promotes wakefulness and alertness. Modafinil is sold under the brand name Provigil among others. Modafinil is used to treat excessive daytime sleepiness due to narcolepsy, shift work sleep disorder, or obstructive sleep apnea. While it has seen off-label use as a purported cognitive enhancer, the research on its effectiveness for this use is not conclusive.[168] Despite being a CNS stimulant, the addiction and dependence liabilities of modafinil are considered very low.[169][170][171] Although modafinil shares biochemical mechanisms with stimulant drugs, it is less likely to have mood-elevating properties.[170] The similarities in effects with caffeine are not clearly established.[172][173] Unlike other stimulants, modafinil does not induce a subjective feeling of pleasure or reward, which is commonly associated with euphoria, an intense feeling of well-being. Euphoria is a potential indicator of drug abuse, which is the compulsive and excessive use of a substance despite adverse consequences. In clinical trials, modafinil has shown no evidence of abuse potential, that is why modafinil is considered to have a low risk of addiction and dependence, however, caution is advised.[174][175]
Pitolisant has been shown to be effective and well-tolerated for the treatment of narcolepsy with or without cataplexy.[182][181][180]
Pitolisant is the only non-controlled anti-narcoleptic drug in the US.[180] It has shown minimal abuse risk in studies.[180][183]
Blocking the histamine 3 (H3) autoreceptor increases the activity of histamine neurons in the brain. The H3 autoreceptors regulate histaminergic activity in the central nervous system (and to a lesser extent, the peripheral nervous system) by inhibiting histamine biosynthesis and release upon binding to endogenous histamine.[184] By preventing the binding of endogenous histamine at the H3, as well as producing a response opposite to that of endogenous histamine at the receptor (inverse agonism), pitolisant enhances histaminergic activity in the brain.[185]
Serotonin 5-HT2A receptor agonists have been found to increase dopamine levels in brain areas like the frontal cortex, striatum, and nucleus accumbens in animal studies.[204][205][206][207] Relatedly, serotonin 5-HT2A receptor agonists are known to produce stimulant-like effects in animals such as hyperlocomotion (increased locomotor activity)[208] and pro-motivational effects.[188][192] The serotonin 5-HT2C receptor, which most psychedelics additionally activate to varying degrees, is known to have opposing effects on dopamine release and stimulant-related behavior, which may contribute to inverted U-shaped dose–response relationships as well as divergent stimulant-like effects between different psychedelics.[209][208]
Recreational use and issues of abuse
Stimulants enhance the activity of the central and peripheral nervous systems. Common effects may include increased alertness, awareness, wakefulness, endurance, productivity, and motivation, arousal, locomotion, heart rate, and blood pressure, and a diminished desire for food and sleep. Use of stimulants may cause the body to reduce significantly its production of natural body chemicals that fulfill similar functions. Until the body reestablishes its normal state, once the effect of the ingested stimulant has worn off the user may feel depressed, lethargic, confused, and miserable. This is referred to as a "crash", and may provoke reuse of the stimulant.
Abuse of central nervous system (CNS) stimulants is common. Addiction to some CNS stimulants can quickly lead to medical, psychiatric, and psychosocial deterioration. Drug tolerance, dependence, and sensitization as well as a withdrawal syndrome can occur.[210] Stimulants may be screened for in animal discrimination and self-administration models which have high sensitivity albeit low specificity.[211] Research on a progressive ratio self-administration protocol has found amphetamine, methylphenidate, modafinil, cocaine, and nicotine to all have a higher break point than placebo that scales with dose indicating reinforcing effects.[212] A progressive ratio self-administration protocol is a way of testing how much an animal or a human wants a drug by making them do a certain action (like pressing a lever or poking a nose device) to get the drug. The number of actions needed to get the drug increases every time, so it becomes harder and harder to get the drug. The highest number of actions that the animal or human is willing to do to get the drug is called the break point. The higher the break point, the more the animal or human wants the drug. In contrast to the classical stimulants such as amphetamine, the effects of modafinil depend on what the animals or humans have to do after getting the drug. If they have to do a performance task, like solving a puzzle or remembering something, modafinil makes them work harder for it than placebo, and the subjects wanted to self-administer modafinil. But if they had to do a relaxation task, like listening to music or watching a video, the subjects did not want to self-administer modafinil. This suggests that modafinil is more rewarding when it helps the animals or humans do something better or faster, especially considering that modafinil is not commonly abused or depended on by people, unlike other stimulants.[212]
Psychosocial treatments, such as contingency management, have demonstrated improved effectiveness when added to treatment as usual consisting of counseling and/or case-management. This is demonstrated with a decrease in dropout rates and a lengthening of periods of abstinence.[213]
Testing
The presence of stimulants in the body may be tested by a variety of procedures. Serum and urine are the common sources of testing material although saliva is sometimes used. Commonly used tests include chromatography, immunologic assay, and mass spectrometry.[214]
↑ 8.08.18.28.3"Chapter 6: Widely Projecting Systems: Monoamines, Acetylcholine, and Orexin". Nestler, Hyman & Malenka's Molecular Neuropharmacology: A Foundation for Clinical Neuroscience (4th ed.). McGraw Hill. 2020. ISBN9781260456905. "The psychostimulants, cocaine, amphetamine, and methylphenidate, are indirect DA agonists that interact with DA transporters. ... Cognitive control is impaired in several disorders, including attention deficit hyperactivity disorder (ADHD), which is treated with psychostimulants, a term used to describe indirect DA agonists such as methylphenidate and amphetamines that block DAT or cause reverse transport of DA."
↑ 9.09.19.29.39.4"Chapter 16: Reinforcement and Addiction". Nestler, Hyman & Malenka's Molecular Neuropharmacology: A Foundation for Clinical Neuroscience (4th ed.). McGraw Hill. 2020. ISBN9781260456905. "Cocaine, amphetamines, and methamphetamine are the major psychostimulants of abuse. The related drug methylphenidate is also abused, although it is far less potent. ... Recent research has demonstrated the involvement of dopamine transporter trafficking to and from the nerve terminal plasma membrane in the actions of psychostimulants. ... 3,4-Methylenedioxymethamphetamine (MDMA), commonly called ecstasy or Molly, is an amphetamine derivative. It produces a combination of psychostimulant-like and weak LSD-like effects at low doses. Unlike LSD, MDMA is reinforcing—most likely because of its interactions with dopamine systems—and accordingly is subject to compulsive abuse."
↑ 10.010.1"Chapter 14: Higher Cognitive Function and Behavioral Control". Nestler, Hyman & Malenka's Molecular Neuropharmacology: A Foundation for Clinical Neuroscience (4th ed.). McGraw Hill. 2020. ISBN9781260456905. "Such a curve also captures the effects of pharmacologic agents that influence arousal, ranging from psychostimulants and caffeine"
↑"Effects of Modafinil (Provigil) on Memory and Learning in Experimental and Clinical Studies: From Molecular Mechanisms to Behaviour Molecular Mechanisms and Behavioural Effects". Current Molecular Pharmacology16 (4): 507–516. 2023. doi:10.2174/1874467215666220901122824. PMID36056861.
↑Hammerness, Paul G.; Karampahtsis, Chris; Babalola, Ronke; Alexander, Mark E. (1 April 2015). "Attention-deficit/hyperactivity disorder treatment: what are the long-term cardiovascular risks?". Expert Opinion on Drug Safety14 (4): 543–551. doi:10.1517/14740338.2015.1011620. ISSN1744-764X. PMID25648243.
↑Hechtman, Lily; Greenfield, Brian (1 January 2003). "Long-term use of stimulants in children with attention deficit hyperactivity disorder: safety, efficacy, and long-term outcome". Paediatric Drugs5 (12): 787–794. doi:10.2165/00148581-200305120-00002. ISSN1174-5878. PMID14658920.
↑Sordo, L; Indave, BI; Barrio, G; Degenhardt, L; de la Fuente, L; Bravo, MJ (1 September 2014). "Cocaine use and risk of stroke: a systematic review.". Drug and Alcohol Dependence142: 1–13. doi:10.1016/j.drugalcdep.2014.06.041. PMID25066468.
↑COUGHLIN, P; MAVOR, A (1 October 2006). "Arterial Consequences of Recreational Drug Use". European Journal of Vascular and Endovascular Surgery32 (4): 389–396. doi:10.1016/j.ejvs.2006.03.003. PMID16682239.
↑Harper, S. J.; Jones, N. S. (1 October 2006). "Cocaine: what role does it have in current ENT practice? A review of the current literature". The Journal of Laryngology and Otology120 (10): 808–811. doi:10.1017/S0022215106001459. ISSN1748-5460. PMID16848922.
↑Palamara, Kerri L.; Mogul, Harriette R.; Peterson, Stephen J.; Frishman, William H. (1 October 2016). "Obesity: new perspectives and pharmacotherapies". Cardiology in Review14 (5): 238–258. doi:10.1097/01.crd.0000233903.57946.fd. ISSN1538-4683. PMID16924165.
↑Bicopoulos D, editor. AusDI: Drug information for the healthcare professional, 2nd edition. Castle Hill: Pharmaceutical Care Information Services; 2002.
↑"Efficacy and tolerability of lisdexamfetamine as an antidepressant augmentation strategy: A meta-analysis of randomized controlled trials". J Affect Disord226: 294–300. January 2018. doi:10.1016/j.jad.2017.09.041. PMID29028590.
↑"The Efficacy of Psychostimulants in Major Depressive Episodes: A Systematic Review and Meta-Analysis". J Clin Psychopharmacol37 (4): 412–418. August 2017. doi:10.1097/JCP.0000000000000723. PMID28590365.
↑"Comparative efficacy and safety of stimulant-type medications for depression: A systematic review and network meta-analysis". J Affect Disord292: 416–423. September 2021. doi:10.1016/j.jad.2021.05.119. PMID34144366.
↑"Development of a non-human primate model to support CNS translational research: Demonstration with D-amphetamine exposure and dopamine response". J Neurosci Methods317: 71–81. April 2019. doi:10.1016/j.jneumeth.2019.02.005. PMID30768951.
↑"Development of a Semimechanistic Pharmacokinetic-Pharmacodynamic Model Describing Dextroamphetamine Exposure and Striatal Dopamine Response in Rats and Nonhuman Primates following a Single Dose of Dextroamphetamine". J Pharmacol Exp Ther369 (1): 107–120. April 2019. doi:10.1124/jpet.118.254508. PMID30733244.
↑van Gaalen, Marcel M.; Schlumbohm, Christina; Folgering, Joost H.; Adhikari, Saugat; Bhattacharya, Chandrali; Steinbach, Douglas; Stratford, Robert E. (7 February 2019). "Development of a Semimechanistic Pharmacokinetic-Pharmacodynamic Model Describing Dextroamphetamine Exposure and Striatal Dopamine Response in Rats and Nonhuman Primates following a Single Dose of Dextroamphetamine". Journal of Pharmacology and Experimental Therapeutics (American Society for Pharmacology & Experimental Therapeutics (ASPET)) 369 (1): 107–120. doi:10.1124/jpet.118.254508. ISSN0022-3565. PMID30733244.
↑"Acute tolerance to subjective but not cardiovascular effects of d-amphetamine in normal, healthy men". J Clin Psychopharmacol16 (1): 72–6. February 1996. doi:10.1097/00004714-199602000-00012. PMID8834422.
↑"Effects of repeated oral methamphetamine administration in humans". Psychopharmacology (Berl)155 (4): 397–404. June 2001. doi:10.1007/s002130100727. PMID11441429.
↑"Neural substrates of psychostimulant withdrawal-induced anhedonia". Behavioral Neuroscience of Drug Addiction. Current Topics in Behavioral Neurosciences. 3. Berlin, Heidelberg. 2010. pp. 119–78. doi:10.1007/7854_2009_20. ISBN978-3-642-03000-0.
↑ 70.0070.0170.0270.0370.0470.0570.0670.0770.0870.0970.1070.1170.12"Biosynthesis of amphetamine analogs in plants". Trends Plant Sci.17 (7): 404–412. 2012. doi:10.1016/j.tplants.2012.03.004. PMID22502775. Bibcode: 2012TPS....17..404H. "Substituted amphetamines, which are also called phenylpropylamino alkaloids, are a diverse group of nitrogen-containing compounds that feature a phenethylamine backbone with a methyl group at the α-position relative to the nitrogen (Figure 1). Countless variation in functional group substitutions has yielded a collection of synthetic drugs with diverse pharmacological properties as stimulants, empathogens and hallucinogens [3]. ... Beyond (1R,2S)-ephedrine and (1S,2S)-pseudoephedrine, myriad other substituted amphetamines have important pharmaceutical applications. The stereochemistry at the α-carbon is often a key determinant of pharmacological activity, with (S)-enantiomers being more potent. For example, (S)-amphetamine, commonly known as d-amphetamine or dextroamphetamine, displays five times greater psychostimulant activity compared with its (R)-isomer [78]. Most such molecules are produced exclusively through chemical syntheses and many are prescribed widely in modern medicine. For example, (S)-amphetamine (Figure 4b), a key ingredient in Adderall and Dexedrine, is used to treat attention deficit hyperactivity disorder (ADHD) [79]. ... [Figure 4](b) Examples of synthetic, pharmaceutically important substituted amphetamines.".
↑ 71.071.1Glennon RA (2013). Foye's principles of medicinal chemistry (7th ed.). Philadelphia, USA: Wolters Kluwer Health/Lippincott Williams & Wilkins. pp. 646–648. ISBN978-1-60913-345-0. "The simplest unsubstituted phenylisopropylamine, 1-phenyl-2-aminopropane, or amphetamine, serves as a common structural template for hallucinogens and psychostimulants. Amphetamine produces central stimulant, anorectic, and sympathomimetic actions, and it is the prototype member of this class (39)."
↑"Determination of ring- and N-substituted amphetamines as heptafluorobutyryl derivatives". Forensic Sci. Int.49 (2): 205–213. March 1991. doi:10.1016/0379-0738(91)90081-s. PMID1855720.
↑"Update on the pharmacologic management of narcolepsy: mechanisms of action and clinical implications". Sleep Medicine68: 97–109. April 2020. doi:10.1016/j.sleep.2019.09.001. PMID32032921.
↑"Modafinil". Prescriber's Guide: Stahl's Essential Psychopharmacology (6th ed.). Cambridge, United Kingdom: Cambridge University Press. March 2017. pp. 491–495. ISBN978-1-108-22874-9.
↑ 86.086.1"Nutritional supplements and ergogenic AIDS". Prim. Care40 (2): 487–505. June 2013. doi:10.1016/j.pop.2013.02.009. PMID23668655. "Amphetamines and caffeine are stimulants that increase alertness, improve focus, decrease reaction time, and delay fatigue, allowing for an increased intensity and duration of training... Physiologic and performance effects • Amphetamines increase dopamine/norepinephrine release and inhibit their reuptake, leading to central nervous system (CNS) stimulation • Amphetamines seem to enhance athletic performance in anaerobic conditions 39 40 • Improved reaction time • Increased muscle strength and delayed muscle fatigue • Increased acceleration • Increased alertness and attention to task".
↑ 87.087.187.2"Chapter 13: Higher Cognitive Function and Behavioral Control". Molecular Neuropharmacology: A Foundation for Clinical Neuroscience (2nd ed.). New York: McGraw-Hill Medical. 2009. p. 318. ISBN978-0-07-148127-4. "Therapeutic (relatively low) doses of psychostimulants, such as methylphenidate and amphetamine, improve performance on working memory tasks both in individuals with ADHD and in normal subjects...it is now believed that dopamine and norepinephrine, but not serotonin, produce the beneficial effects of stimulants on working memory. At abused (relatively high) doses, stimulants can interfere with working memory and cognitive control, as will be discussed below. It is important to recognize, however, that stimulants act not only on working memory function, but also on general levels of arousal and, within the nucleus accumbens, improve the saliency of tasks. Thus, stimulants improve performance on effortful but tedious tasks...through indirect stimulation of dopamine and norepinephrine receptors."
↑"Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature". J. Am. Acad. Child Adolesc. Psychiatry47 (1): 21–31. January 2008. doi:10.1097/chi.0b013e31815a56f1. PMID18174822. "Stimulant misuse appears to occur both for performance enhancement and their euphorogenic effects, the latter being related to the intrinsic properties of the stimulants (e.g., IR versus ER profile)...
Although useful in the treatment of ADHD, stimulants are controlled II substances with a history of preclinical and human studies showing potential abuse liability.".
↑Rasmussen N (July 2006). "Making the first anti-depressant: amphetamine in American medicine, 1929–1950". J. Hist. Med. Allied Sci.61 (3): 288–323. doi:10.1093/jhmas/jrj039. PMID16492800.
↑Nehlig, A.; Daval, J. L.; Debry, G. (1 August 2016). "Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects". Brain Research. Brain Research Reviews17 (2): 139–170. doi:10.1016/0165-0173(92)90012-b. PMID1356551.
↑"Oligomerization of adenosine A2A and dopamine D2 receptors in living cells". Biochemical and Biophysical Research Communications306 (2): 544–9. Jun 2003. doi:10.1016/S0006-291X(03)00991-4. PMID12804599.
↑"Caffeine intake and dementia: systematic review and meta-analysis". J. Alzheimers Dis.20 (Suppl 1): S187–204. 2010. doi:10.3233/JAD-2010-091387. PMID20182026.
↑"Modulating Alzheimer's disease through caffeine: a putative link to epigenetics". J. Alzheimers Dis.24 (2): 161–71. 2011. doi:10.3233/JAD-2011-110032. PMID21427489.
↑"Caffeine and coffee as therapeutics against Alzheimer's disease". J. Alzheimers Dis.20 (Suppl 1): S117–26. 2010. doi:10.3233/JAD-2010-091249. PMID20182037.
↑van Dam RM (2008). "Coffee consumption and risk of type 2 diabetes, cardiovascular diseases, and cancer". Applied Physiology, Nutrition, and Metabolism33 (6): 1269–1283. doi:10.1139/H08-120. PMID19088789.
↑"Habitual coffee consumption and risk of hypertension: a systematic review and meta-analysis of prospective observational studies". Am. J. Clin. Nutr.93 (6): 1212–9. June 2011. doi:10.3945/ajcn.110.004044. PMID21450934.
↑"The effect of caffeine on intraocular pressure: a systematic review and meta-analysis". Graefes Arch. Clin. Exp. Ophthalmol.249 (3): 435–42. March 2011. doi:10.1007/s00417-010-1455-1. PMID20706731.
↑ 140.0140.1140.2"15". Molecular Neuropharmacology: A Foundation for Clinical Neuroscience (2nd ed.). New York: McGraw-Hill Medical. 2009. p. 370. ISBN978-0-07-148127-4. "Unlike cocaine and amphetamine, methamphetamine is directly toxic to midbrain dopamine neurons."
↑ 142.0142.1142.2142.3"Methamphetamine toxicity and messengers of death". Brain Res. Rev.60 (2): 379–407. May 2009. doi:10.1016/j.brainresrev.2009.03.002. PMID19328213. "Neuroimaging studies have revealed that METH can indeed cause neurodegenerative changes in the brains of human addicts (Aron and Paulus, 2007; Chang et al., 2007). These abnormalities include persistent decreases in the levels of dopamine transporters (DAT) in the orbitofrontal cortex, dorsolateral prefrontal cortex, and the caudate-putamen (McCann et al., 1998, 2008; Sekine et al., 2003; Volkow et al., 2001a, 2001c). The density of serotonin transporters (5-HTT) is also decreased in the midbrain, caudate, putamen, hypothalamus, thalamus, the orbitofrontal, temporal, and cingulate cortices of METH-dependent individuals (Sekine et al., 2006) ... Neuropsychological studies have detected deficits in attention, working memory, and decision-making in chronic METH addicts ... There is compelling evidence that the negative neuropsychiatric consequences of METH abuse are due, at least in part, to drug-induced neuropathological changes in the brains of these METH-exposed individuals ... Structural magnetic resonance imaging (MRI) studies in METH addicts have revealed substantial morphological changes in their brains. These include loss of gray matter in the cingulate, limbic, and paralimbic cortices, significant shrinkage of hippocampi, and hypertrophy of white matter (Thompson et al., 2004). In addition, the brains of METH abusers show evidence of hyperintensities in white matter (Bae et al., 2006; Ernst et al., 2000), decreases in the neuronal marker, N-acetylaspartate (Ernst et al., 2000; Sung et al., 2007), reductions in a marker of metabolic integrity, creatine (Sekine et al., 2002) and increases in a marker of glial activation, myoinositol (Chang et al., 2002; Ernst et al., 2000; Sung et al., 2007; Yen et al., 1994). Elevated choline levels, which are indicative of increased cellular membrane synthesis and turnover are also evident in the frontal gray matter of METH abusers (Ernst et al., 2000; Salo et al., 2007; Taylor et al., 2007).".
↑"Meta-analysis of functional magnetic resonance imaging studies of inhibition and attention in attention-deficit/hyperactivity disorder: exploring task-specific, stimulant medication, and age effects". JAMA Psychiatry70 (2): 185–198. February 2013. doi:10.1001/jamapsychiatry.2013.277. PMID23247506.
↑AJ Giannini; WC Price (1986). "Contemporary drugs of abuse". American Family Physician33: 207–213.
↑Talhouth, Reinskje; Opperhuizen, Antoon; van Amsterdam G. C., Jan (October 2007). "Role of acetaldehyde in tobacco smoke addiction". European Neuropsychopharmacology17 (10): 627–636. doi:10.1016/j.euroneuro.2007.02.013. PMID17382522.
↑Flavahan NA (April 2005). "Phenylpropanolamine constricts mouse and human blood vessels by preferentially activating alpha2-adrenoceptors". Journal of Pharmacology and Experimental Therapeutics313 (1): 432–9. doi:10.1124/jpet.104.076653. PMID15608085.
↑Hunter Gillies; Wayne E. Derman; Timothy D. Noakes; Peter Smith; Alicia Evans; Gary Gabriels (1 December 1996). "Pseudoephedrine is without ergogenic effects during prolonged exercise". Journal of Applied Physiology81 (6): 2611–2617. doi:10.1152/jappl.1996.81.6.2611. PMID9018513.
↑Hodges, K; Hancock S; Currel K; Hamilton B; Jeukendrup AE (Feb 2006). "Pseudoephedrine enhances performance in 1500-m runners". Medicine and Science in Sports and Exercise38 (2): 329–33. doi:10.1249/01.mss.0000183201.79330.9c. PMID16531903.
↑Haight-Ashbury Free Medical Clinic, Journal of psychoactive drugs, Volume 41, (Haight-Ashbury Publications: 2009), p.3.
↑Kredlow, M Alexandra; Keshishian, Ani; Oppenheimer, Sarah; Otto, Michael W (1 September 2019). "The Efficacy of Modafinil as a Cognitive Enhancer: A Systematic Review and Meta-Analysis". Journal of Clinical Psychopharmacology39 (5): 455–461. doi:10.1097/jcp.0000000000001085. PMID31433334.
↑"A Review of Pharmacologic Neurostimulant Use During Rehabilitation and Recovery After Brain Injury". Ann Pharmacother55 (10): 1254–1266. October 2021. doi:10.1177/1060028020983607. PMID33435717.
↑"Subjective effects of modafinil, a new central adrenergic stimulant in healthy volunteers: a comparison with amphetamine, caffeine and placebo". European Psychiatry8 (4): 201–208. 1993. doi:10.1017/S0924933800002923.
↑"Modafinil". StatPearls. Treasure Island (FL): StatPearls Publishing. February 2022. Template:NCBIBook.
↑"Pitolisant". LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases. 24 January 2012. https://www.ncbi.nlm.nih.gov/books/NBK573784/. Retrieved 24 January 2024.
↑ 181.0181.1Kollb-Sielecka, Marta; Demolis, Pierre; Emmerich, Joseph; Markey, Greg; Salmonson, Tomas; Haas, Manuel (1 May 2017). "The European Medicines Agency review of pitolisant for treatment of narcolepsy: summary of the scientific assessment by the Committee for Medicinal Products for Human Use". Sleep Medicine33: 125–129. doi:10.1016/j.sleep.2017.01.002. PMID28449891.
↑ 186.0186.1186.2Kuypers, Kim P. C. (2024). "Microdosing Psychedelics as a Promising New Pharmacotherapeutic". Modern CNS Drug Discovery. Cham: Springer Nature Switzerland. pp. 407–436. doi:10.1007/978-3-031-61992-2_26. ISBN978-3-031-61991-5. https://link.springer.com/10.1007/978-3-031-61992-2_26. Retrieved 28 May 2025. "Interestingly, users sometimes attribute other effects to different psychedelics, in which LSD is more associated with cognitive and/or stimulant effects and psilocybin with emotional or well-being effects (Anderson et al. 2019b; Johnstad 2018). This stronger stimulant character of LSD compared to psilocybin was seen by some as an advantage while others experienced it as uncomfortable (Johnstad 2018). [...] Additionally, McGlothlin et al. (1967) showed that LSD (25 mcg) indeed induces stimulant effects, as the effects were similar to those of amphetamine (20 mg) (McGlothlin et al. 1967). Notwithstanding this does not confirm that psilocybin and LSD would have dissimilar effects; it rather supports the claims by users that LSD in low doses has stimulant effects (Johnstad 2018; Anderson et al. 2019a). [...] Decades earlier, Albert Hofmann, the "discoverer" of LSD and its hallucinogenic effects, mentioned that "very small doses, perhaps 25 micrograms," could be useful as an antidepressant (Ghose 2015; Horowitz 1976) or as a substitute for Ritalin (Fadiman 2017; Horowitz 1976)."
↑"Serotonin 5-HT(2A) receptor antagonists in the treatment of insomnia: present status and future prospects". Drugs Today (Barc)46 (3): 183–193. March 2010. doi:10.1358/dot.2010.46.3.1437247. PMID20467592. "Systemic administration of the nonselective 5-HT2A receptor agonists DOI (1-[2,5-dimethoxy-4-iodophenyl]- 2-aminopropane) and DOM (1-[2,5-dimethoxy-4- methylphenyl]-2-aminopropane) has been shown to reduce SWS and REM sleep, and to augment wakefulness in the rat (47-49) (Table I). In addition, systemic or intrathalamic injection of DOI decreased the neocortical high-voltage spindle activity that occurs during relaxed wakefulness in the rat (50).".
↑"Population Survey Data Informing the Therapeutic Potential of Classic and Novel Phenethylamine, Tryptamine, and Lysergamide Psychedelics". Front Psychiatry10. 2019. doi:10.3389/fpsyt.2019.00896. PMID32116806. "In support of this view, 2C-B, the most commonly reported novel phenethylamine, is often substituted for MDMA among electronic music party goers secondary to its purported psychostimulant properties (15, 20, 65). Indeed, novel phenethylamines are often described in terms of psychostimulant effects (20, 29), whereas challenging, emotional breakthrough, and mystical-type experiences appear to underlie the therapeutic outcomes of the classic tryptamine psychedelic psilocybin (16, 66, 67). [...] As noted above, the novel phenethylamine 2C-B may have a reputation as a “party drug, ” and thus the associations reported here may reflect the influence of recreational use motives.".
↑"Assessment of the Acute Effects of 2C-B vs. Psilocybin on Subjective Experience, Mood, and Cognition". Clin Pharmacol Ther114 (2): 423–433. August 2023. doi:10.1002/cpt.2958. PMID37253161.
↑"The Effects of Psychedelics on Neuronal Physiology". Annu Rev Physiol86: 27–47. February 2024. doi:10.1146/annurev-physiol-042022-020923. PMID37931171. "Systemic administration of psilocybin in rats rapidly increased dopamine release in the PFC (78), suggesting that psilocin regulates a known top-down neurocircuit involving 5-HT2ARexpressing pyramidal neurons that project to and activate mesocortical dopaminergic VTA neurons. Indeed, activation of 5-HT2ARs in the PFC by DOI increases mesocortical dopaminergic signaling (134), and 25I-NBOMe dose-dependently increases dopamine in the frontal cortex (129). DOI and psilocin also activate mesolimbic dopaminergic VTA neurons, increasing dopamine release in the nucleus accumbens (135, 136).".